CMS proposes new drug pricing model to expand GLP-1 access to those with Medicare Part D and Medicaid
The Centers for Medicare & Medicaid Services Dec. 23 introduced a l for Medicare Part D and Medicaid beneficiaries. The Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth would increase access to glucagon-like peptide-1 (GLP-1) medications — used for weight loss and other health needs — and other healthy lifestyle interventions. As part of the BALANCE model, CMS will negotiate drug pricing and coverage terms on behalf of state Medicaid agencies and Medicare Part D plan sponsors.
State Medicaid agencies can join the model beginning May 2026, and Part D plans in January 2027.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 18 that it will launch a voluntary payment model designed to broadly reach more…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program. “When…
Blog
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…